Location: Amsterdam, Netherlands
Date: June 13 to June 16
The 24th Congress of the European Hematology Association.
The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: INTERIM phase 1B/2 results
Breaking down diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukaemia therapy
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: results from a randomized HOVON-NORDIC Lymphoma group phase III study
CPI-0610, a bromodomain and extraterminal domain inhibitor, reduces pro-inflammatory cytokines, bone marrow fibrosis and the number of transfusions in myelofibrosis patients
Targeting aberrant DNA methylation as a novel and uniform therapeutic strategy for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
ASCEND Phase 3 study of acalabrutinib vs investigator's choice of rituximab plus idelalisib or bendamustine in patients with relapsed/refractory chronic lymphocytic leukemia
A randomized controlled phase III clinical trial comparing recombinant interferon alpha-2 vs. hydroxyurea in patients with myeloproliferative neoplasms -Three-year analysis of the DALIAH trial
Sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anemia
Is iron chelation really necessary in MDS?
Complex evaluation of cellular and humoral immunity in patients with chronic lymphocytic leukemia
NGS technologies in AML: Time to use in clinical care?
Large B-cell lymphomas
Tipifernib in relapsed or refractory angioimmunoblastic T-cell lymphoma and CXCL12+ peripheral T-cell lymphoma
Results from the randomized placebo- controlled phese 3 HOPE trial of voxelotor in adults and adolescents with sickle cell disease
Immunotherapy in relapsed/refractory multiple myeloma
New therapies in AML
EHA: Call for urgent action on medicine shortages in Europe
EHA: Recommendation for hematologists in COVID-19 crisis